NASDAQ:ERNA Ernexa Therapeutics (ERNA) Stock Price, News & Analysis $6.27 0.00 (0.00%) Closing price 07/2/2026 03:59 PM EasternExtended Trading$6.20 -0.06 (-1.04%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Ernexa Therapeutics Stock (NASDAQ:ERNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ernexa Therapeutics alerts:Sign Up Key Stats Today's Range$6.26▼$6.9250-Day Range$3.69▼$13.6352-Week Range$3.18▼$71.50Volume13,908 shsAverage Volume54,455 shsMarket Capitalization$7.34 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingHold Company Overview Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts. Read More Ernexa Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreERNA MarketRank™: Ernexa Therapeutics scored higher than 75% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingErnexa Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialErnexa Therapeutics has a consensus price target of $30.00, representing about 378.5% upside from its current price of $6.27.Amount of Analyst CoverageErnexa Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Ernexa Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ernexa Therapeutics are expected to grow in the coming year, from ($18.02) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ernexa Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ernexa Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErnexa Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Ernexa Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.50% of the float of Ernexa Therapeutics has been sold short.Short Interest Ratio / Days to CoverErnexa Therapeutics has a short interest ratio ("days to cover") of 0.89, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ernexa Therapeutics has recently decreased by 9.39%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldErnexa Therapeutics does not currently pay a dividend.Dividend GrowthErnexa Therapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.19 News SentimentErnexa Therapeutics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Ernexa Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ernexa Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.53% of the stock of Ernexa Therapeutics is held by insiders.Percentage Held by Institutions70.55% of the stock of Ernexa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ernexa Therapeutics' insider trading history. Receive ERNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ernexa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ERNA Stock News HeadlinesEterna Therapeutics Updates Investor Presentation, Highlights Web DisclosuresJuly 2 at 5:11 PM | tipranks.comEterna Therapeutics Holds 2026 Annual Stockholder MeetingJuly 2 at 5:11 PM | tipranks.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.July 4 at 1:00 AM | Porter & Company (Ad)Critical Contrast: Addex Therapeutics (NASDAQ:ADXN) vs. Ernexa Therapeutics (NASDAQ:ERNA)July 2 at 4:43 AM | americanbankingnews.comErnexa Therapeutics (NASDAQ:ERNA) Raised to Hold at Wall Street ZenJune 27, 2026 | americanbankingnews.comErnexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for PatientsJune 25, 2026 | globenewswire.comErnexa Therapeutics Inc.: Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in ...June 17, 2026 | finanznachrichten.deErnexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human StudyJune 17, 2026 | globenewswire.comSee More Headlines ERNA Stock Analysis - Frequently Asked Questions How have ERNA shares performed this year? Ernexa Therapeutics' stock was trading at $30.00 at the beginning of 2026. Since then, ERNA stock has decreased by 79.1% and is now trading at $6.27. How were Ernexa Therapeutics' earnings last quarter? Ernexa Therapeutics Inc. (NASDAQ:ERNA) issued its quarterly earnings data on Monday, May, 11th. The company reported ($6.95) earnings per share for the quarter, missing analysts' consensus estimates of ($1.95) by $5.00. When did Ernexa Therapeutics' stock split? Shares of Ernexa Therapeutics reverse split on the morning of Monday, May 4th 2026.The 1-25 reverse split was announced on Thursday, April 30th 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 1st 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Ernexa Therapeutics? Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ernexa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ernexa Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Company Calendar Last Earnings5/11/2026Today7/04/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4d) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 As of 4 days ago, ERNA's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ERNA CIK748592 Webwww.brooklynitx.com Phone(212) 582-1199Fax760-438-3505Employees10Year Founded1953Price Target and Rating Average Price Target for Ernexa Therapeutics$30.00 High Price Target$30.00 Low Price Target$30.00 Potential Upside/Downside+378.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($26.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.08 million Net MarginsN/A Pretax MarginN/A Return on Equity-263.74% Return on Assets-151.16% Debt Debt-to-Equity RatioN/A Current Ratio2.89 Quick Ratio2.89 Sales & Book Value Annual Sales$580 thousand Price / Sales12.65 Cash FlowN/A Price / Cash FlowN/A Book Value$7.64 per share Price / Book0.82Miscellaneous Outstanding Shares1,170,000Free Float1,160,000Market Cap$7.34 million OptionableNo Data Beta2.50 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ERNA) was last updated on 7/4/2026 by MarketBeat.com Staff. From Our PartnersHe turned $12,415 into millions. Now he wants to help you.Tim Sykes turned $12,415 in bar mitzvah money into over $7 million in trading profits - and more than 50 of hi...Tim Sykes | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredThe pre-flight check for options tradersPilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Che...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredThe energy story near the Grand CanyonA drilling crew near the Grand Canyon confirmed what the IEA calls one of the largest energy resources ever me...Behind the Markets | SponsoredAre we ignoring the same signal Wall Street ignored in 1929?In 1929, a 20-something broker named Irving Weiss shorted the market before Black Monday and made a fortune. H...Weiss Ratings | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ernexa Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ernexa Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
